FIND & NDWG Symposium
Jointly organized by FIND and the New Diagnostics Working Group

Wednesday 11 October 2017, 13:00 - 17:00
Expo Convention Center, Guadalajara, Mexico
Hall 9 Jalisco Hall

Agenda on back
Chairpersons
Catharina Boehme, Chief Executive Officer, FIND and NDWG Co-Chair
Daniela Cirillo, Head Emerging Bacterial Pathogens Unit, San Raffaele Scientific Institute and NDWG Co-Chair

13:00-14:00 The global TB diagnostics pipeline: Progress and needs
- Welcome address, Catharina Boehme and Daniela Cirillo
- Overview and updates on recent developments against needs, Claudia Denkinger, FIND
- The funding gap in TB diagnostics R&D – Results from report on TB research funding trends, Erica Lessem, TAG
- Highlights and new promising technologies
  - Use of genome-wide expression for diagnosing active TB and potential for non-sputum based diagnosis, Purvesh Khatri, Stanford University
  - Potential of cell-free DNA in plasma or urine for rapid detection of *Mycobacterium tuberculosis*, Niaz Banaei, Stanford University

14:00-14:45 Supporting development of new tests for LTBI: Recent advances
- Incipient TB assays to support TB elimination: Opportunities and challenges, Samuel Schumacher, FIND
- Estimating the impact of a test for incipient TB: Preliminary results of a transmission and cost effectiveness model, Suzanne Verver, Erasmus University Medical Center
- The current landscape of discovery and early development in LTBI and incipient TB, Gavin Churchyard, Aurum Institute

14:45-15:15 Coffee break

15:15-16:00 Progress in the use of next-generation sequencing (NGS) for surveillance, diagnosis and patient management
- Programmatic Implementation of NGS for TB and future plans for the ReSeqTB knowledgebase, Timothy Rodwell, FIND / UCSD
- Predicting susceptibility to first-line drugs: Can we phase out phenotypic DST and transition to WGS-led diagnostics? Timothy Walker, University of Oxford
- WHO policy update: Interpretation of DST, Christopher Gilpin, World Health Organization

16:00-17:00 Panel discussion: Challenges in molecular testing roll-out on a programmatic level
Panelists will consider how the interpretation of genetic mutations can guide clinical decision for treatment and will share different perspectives about the prospects of scaling up molecular approaches in different settings.

Moderator: Martina Casenghi, Core Group New Diagnostics Working Group
Panelists:
- Stephanie Denamps, Clinton Health Access Initiative
- Gunta Dravniece, KNCV Tuberculosis Foundation
- Kathleen England, MSF Access Campaign
- David Mameța, National TB Programme Manager, South Africa (TBC)
- Kaiser Shen, USAID